Clinical trial NCT02003924: Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Official title: PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Nonmetastatic Castration-Resistant Prostate Cancer
Prostate Cancer
Cancer of the Prostate
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
Collaborators: name: Astellas Pharma Inc
name: Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
First posted: 2013-12-06
Enrollment: 1401
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.


Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell, or small cell features;
* Ongoing androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) agonist/antagonist or prior bilateral orchiectomy (medical or surgical castration);
* Testosterone ≤ 50 ng/dL (≤ 1.73 nmol/L) at screening;
* Progressive disease on androgen deprivation therapy at enrollment;
* PSA and the screening PSA assessed by the central laboratory (central PSA) should be ≥ 2 µg/L (2 ng/mL:
* PSA doubling time ≤ 10 months;
* No prior or present evidence of metastatic disease;
* Asymptomatic prostate cancer;
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
* Estimated life expectancy ≥ 12 months.

Exclusion Criteria:

* Prior cytotoxic chemotherapy;
* Use of hormonal therapy or biologic therapy for prostate cancer (other than approved bone targeting agents and GnRH agonist/antagonist therapy) or use of an investigational agent within 4 weeks of randomization;
* Known or suspected brain metastasis or active leptomeningeal disease;
* History of another invasive cancer within 3 years of randomization;
* Absolute neutrophil count \< 1000/μL, platelet count \< 100,000/μL, or hemoglobin \< 10 g/dL (6.2 mmol/L) at screening;
* Total bilirubin ≥ 1.5 times the upper limit of normal;
* Creatinine \> 2 mg/dL (177 µmol/L) at screening;
* Albumin \< 3.0 g/dL (30 g/L) at screening;
* History of seizure or any condition that may predispose to seizure;
* Clinically significant cardiovascular disease;
* Gastrointestinal disorder affecting absorption;
* Major surgery within 4 weeks of randomization;
* Hypersensitivity reaction to the active pharmaceutical ingredient or any of the capsule components, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene;
* Any concurrent disease, infection, or comorbid condition that interferes with the ability of the patient to participate in the trial, which places the patient at undue risk, or complicates the interpretation of data, in the opinion of the investigator or medical monitor.

Primary outcomes:
measure: Metastasis Free Survival (MFS)
timeFrame: From randomization until radiographic progression at any time, or death within 112 days of treatment discontinuation, whichever occurred first (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)
Secondary outcomes:
measure: Time to Prostate-Specific Antigen (PSA) Progression
timeFrame: From randomization until first PSA progression (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)
measure: Time to First Use of New Antineoplastic Therapy
timeFrame: From randomization until first use of new antineoplastic therapy(until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)
measure: Overall Survival
timeFrame: From randomization until death (up to a maximum of 68.8 months)
measure: Time to Pain Progression
timeFrame: From randomization until onset of pain progression (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)
measure: Time to First Use of Cytotoxic Chemotherapy
timeFrame: From randomization up to the first use of cytotoxic chemotherapy (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)
measure: Chemotherapy-Free Disease Specific Survival
timeFrame: From randomization up to first use of cytotoxic chemotherapy for prostate cancer or death due to prostate cancer (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)
measure: Chemotherapy-Free Survival
timeFrame: From randomization up to first use of cytotoxic chemotherapy for prostate cancer or death due to any cause (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)
measure: Percentage of Participants With Prostate Specific Antigen (PSA) Response
timeFrame: From randomization until first PSA progression (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)
measure: Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Mobility Domain Score
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Self-Care Domain Score
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Usual Activities Domain Score
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Pain/Discomfort Domain Score
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Anxiety/ Depression Domain Score
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Overall Health Status Visual Analog Score (VAS)
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 31
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 32
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 33
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 34
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 35
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 36
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 37
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 38
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 39
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 40
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 41
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 42
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 43
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 44
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 45
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 46
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 47
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 48
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 49
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 50
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 51
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 52
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 53
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 54
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 55
timeFrame: Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177
measure: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: From first dose of study drug to the last dose + 30 days (or the day before initiation of a new antineoplastic treatment, whichever occurred first) (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)
measure: Number of Participants With Treatment-Emergent Adverse Events Greater Than or Equal to Grade 3, Based on National Cancer Institute (NCI) Common Terminology Criteria (CTC) for AEs (CTCAE), Version 4.0
timeFrame: From first dose of study drug to the last dose + 30 days (or the day before initiation of a new antineoplastic treatment, whichever occurred first) (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)
measure: Number of Participants With Discontinuations From Study Treatment Due to Adverse Events (AEs)
timeFrame: From first dose of study drug to the last dose + 30 days (or the day before initiation of a new antineoplastic treatment, whichever occurred first) (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)
measure: Number of Participants With Increase of 2 or More National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) (Version 4.0) Toxicity Grades Above Baseline - Hematology
timeFrame: From first dose of study drug to the last dose + 30 days (or the day before initiation of a new antineoplastic treatment, whichever occurred first) (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)
measure: Number of Participants With Increase of 2 or More National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) (Version 4.0) Toxicity Grades Above Baseline - Chemistry
timeFrame: From first dose of study drug to the last dose + 30 days (or the day before initiation of a new antineoplastic treatment, whichever occurred first) (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)
measure: Number of Participants With Clinically Significant Vital Signs
timeFrame: From first dose of study drug to the last dose + 30 days (or the day before initiation of a new antineoplastic treatment, whichever occurred first) (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Urological Associates of Southern Arizona, PC
state: Arizona
city: Los Angeles
country: United States
facility: Ronald Reagan UCLA Medical Center
state: California
city: Los Angeles
country: United States
facility: UCLA Clark Urology Center
state: California
city: Orange
country: United States
facility: University of California, Irvine Medical Center
state: California
city: San Luis Obispo
country: United States
facility: Urology Associates of San Luis Obispo, a Medical Group, Inc
state: California
city: Englewood
country: United States
facility: Urology Associates, P.C.
state: Colorado
city: New Haven
country: United States
facility: c/o Lynn Buchwalder
state: Connecticut
city: New Haven
country: United States
facility: C/O Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven
state: Connecticut
city: New Haven
country: United States
facility: Smilow Cancer Center at Yale New Haven-Hospital
state: Connecticut
city: New Haven
country: United States
facility: Yale New Haven Hospital
state: Connecticut
city: New Haven
country: United States
facility: Yale University School of Medicine
state: Connecticut
city: Lakeland
country: United States
facility: Lakeland Regional Cancer Center
state: Florida
city: Carmel
country: United States
facility: Urology of Indiana, LLC
state: Indiana
city: Jeffersonville
country: United States
facility: First Urology, PSC
state: Indiana
city: Lafayette
country: United States
facility: IU Health Arnett Cancer Care
state: Indiana
city: Overland Park
country: United States
facility: Kansas City Urology Care, PA
state: Kansas
city: Wichita
country: United States
facility: GU Research Network/ Wichita Urology Group
state: Kansas
city: Baltimore
country: United States
facility: Chesapeake Urology Research Associates
state: Maryland
city: Ann Arbor
country: United States
facility: University of Michigan Health System
state: Michigan
city: Troy
country: United States
facility: Michigan Institute of Urology
state: Michigan
city: Omaha
country: United States
facility: GU Research Network
state: Nebraska
city: Brooklyn
country: United States
facility: Brooklyn Urology Research Group
state: New York
city: Newburgh
country: United States
facility: Premier Medical Group of the Hudson Valley
state: New York
city: Cary
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Charlotte
country: United States
facility: Carolina Urology Partners, PLLC
state: North Carolina
city: Gastonia
country: United States
facility: Carolina Urology Partners, PLLC
state: North Carolina
city: Gastonia
country: United States
facility: Gaston Medical Associates
state: North Carolina
city: Huntersville
country: United States
facility: Carolina Urology Partners, PLLC
state: North Carolina
city: Raleigh
country: United States
facility: Duke Women's Cancer Care Raleigh
state: North Carolina
city: Middleburg Heights
country: United States
facility: Clinical Research Solutions
state: Ohio
city: Springfield
country: United States
facility: Oregon Urology Institute
state: Oregon
city: Lancaster
country: United States
facility: Lancaster Urology
state: Pennsylvania
city: Myrtle Beach
country: United States
facility: Carolina Urologic Research Center
state: South Carolina
city: Nashville
country: United States
facility: Vanderbilt University Medical Center, Dept. of Urologic Surgery
state: Tennessee
city: Nashville
country: United States
facility: Vanderbilt University Medical Center, The Urologic Clinic
state: Tennessee
city: San Antonio
country: United States
facility: Urology San Antonio
state: Texas
city: Virginia Beach
country: United States
facility: Urology of Virginia, PLLC
state: Virginia
city: Berazategui
country: Argentina
facility: COIBA(Centro de Oncologia e Investigacion Buenos Aires)
state: Buenos Aires
city: Caba
country: Argentina
facility: Centro Medico Austral(OMI)
state: Buenos Aires
city: Caba
country: Argentina
facility: Centro de Urologia
state: Buenos Aires
city: Caba
country: Argentina
facility: Hospital Italiano de Buenos Aires
state: Buenos Aires
city: Rosario
country: Argentina
facility: Sanatorio Parque
state: Santa FE
city: Rosario
country: Argentina
facility: Instituto De Oncologia De Rosario
state: Santa FE
city: Cordoba
country: Argentina
facility: Clinica Universidad Reina Fabiola
city: Cordoba
country: Argentina
facility: Hospital Privado Centro Medico de Cordoba
city: La Rioja
country: Argentina
facility: Centro Oncologico Riojano Integral (CORI)
city: Garran
country: Australia
facility: The Canberra Hospital
state: Australian Capital Territory
city: Albury
country: Australia
facility: Border Medical Oncology Research Unit
state: New South Wales
city: Albury
country: Australia
facility: The Border Cancer Hospital Dispensary
state: New South Wales
city: Albury
country: Australia
facility: The Border Cancer Hospital
state: New South Wales
city: Concord
country: Australia
facility: Sydney cancer centre
state: New South Wales
city: Lismore
country: Australia
facility: Epic pharmacy
state: New South Wales
city: Lismore
country: Australia
facility: North Coast Cancer Institute
state: New South Wales
city: North Ryde
country: Australia
facility: Macquarie University Hospital
state: New South Wales
city: North Ryde
country: Australia
facility: Macquarie University
state: New South Wales
city: Port Macquarie
country: Australia
facility: Epic Pharmacy Port Macquarie base hospital
state: New South Wales
city: Port Macquarie
country: Australia
facility: Mid North Coast Cancer Institute
state: New South Wales
city: St Leonards
country: Australia
facility: Royal North Shore Hospital
state: New South Wales
city: Tweed Heads
country: Australia
facility: The Tweed Hospital
state: New South Wales
city: Wahroonga
country: Australia
facility: Australian Clinical Trials
state: New South Wales
city: Wahroonga
country: Australia
facility: Sydney Adventist Hospital
state: New South Wales
city: Waratah
country: Australia
facility: Calvary Mater Newcastle
state: New South Wales
city: Westmead
country: Australia
facility: Westmead Hospital
state: New South Wales
city: Auchenflower
country: Australia
facility: Icon Cancer Care Wesley
state: Queensland
city: Auchenflower
country: Australia
facility: River City Pharmacy - APHS
state: Queensland
city: Chermside
country: Australia
facility: Icon Cancer Care Chermside
state: Queensland
city: South Brisbane
country: Australia
facility: Icon Cancer Care South Brisbane
state: Queensland
city: South Brisbane
country: Australia
facility: Integrated Clinical Oncology Network (ICON)
state: Queensland
city: Southport
country: Australia
facility: Icon Cancer Care Southport
state: Queensland
city: Southport
country: Australia
facility: Tasman Oncology Research Pty Ltd
state: Queensland
city: Woolloongabba
country: Australia
facility: Princess Alexandra Hospital
state: Queensland
city: Kurralta Park
country: Australia
facility: Adelaide Cancer Centre
state: South Australia
city: Kurralta park
country: Australia
facility: Ashford Cancer Centre Research
state: South Australia
city: Kurralta Park
country: Australia
facility: Cancer Care SA Pty Ltd
state: South Australia
city: Kurralta Park
country: Australia
facility: Tenpharm Pty Ltd trading as EPIC Pharmacy Tennyson
state: South Australia
city: Box Hill
country: Australia
facility: Box Hill Hospital (Eastern health)
state: Victoria
city: Box Hill
country: Australia
facility: Eastern Clinical Research Unit (Eastern Health)
state: Victoria
city: Brighton
country: Australia
facility: Cabrini Hospital Brighton
state: Victoria
city: Clayton
country: Australia
facility: Monash Medical Centre
state: Victoria
city: Heidelberg
country: Australia
facility: Austin Health, Austin Hospital
state: Victoria
city: Malvern
country: Australia
facility: Cabrini Hospital Malvern
state: Victoria
city: Malvern
country: Australia
facility: Cabrini Hospital- Education and Research Precinct
state: Victoria
city: Melbourne
country: Australia
facility: Peter MacCallum Cancer Centre
state: Victoria
city: St Albans
country: Australia
facility: Sunshine Hospital
state: Victoria
city: Linz
country: Austria
facility: Krankenhaus Barmherzige Schwestern Linz, Abteilung Radiologie
state: Upper Austria
city: Linz
country: Austria
facility: Krankenhaus Barmherzige Schwestern Linz, Abteilung Urologie
state: Upper Austria
city: Linz
country: Austria
facility: St. Vincent's Hospital, PET - CT Center
state: Upper Austria
city: Vienna
country: Austria
facility: Isotopix, Ambulatorium fuer Nuklearmedizin
city: Vienna
country: Austria
facility: Medizinische Universitaet Wien, Universitaetsklinik fuer Innere Medizin I
city: Vienna
country: Austria
facility: Diagnosezentrum Meidling GesmbH
city: Kortrijk
country: Belgium
facility: Algemeen Ziekenhuis Groeninge
state: West-vlaanderen
city: Bruxelles
country: Belgium
facility: Clinique Universitaire de Bruxelles Hopital Erasme
city: Gent
country: Belgium
facility: Vzw Algemeen Ziekenhuis Maria Middelares
city: Leuven
country: Belgium
facility: Universitaire Ziekenhuizen Leuven
city: Liege
country: Belgium
facility: Centre Hospitalier Universitaire de Liege, Site du Sart-Tilman
city: Salvador
country: Brazil
facility: Hospital Sao Rafael
state: Bahia
city: Curitiba
country: Brazil
facility: Liga Paranaense de Combate ao cancer / Hospital Erasto Gaertner
state: Parana
city: Ijui
country: Brazil
facility: Associacao Hospital de Caridade de Ijui
state: RIO Grande DO SUL
city: Passo Fundo
country: Brazil
facility: Hospital da Cidade de Passo Fundo
state: RIO Grande DO SUL
city: Porto Alegre
country: Brazil
facility: Hospital de Clinicas de Porto Alegre
state: RIO Grande DO SUL
city: Porto Alegre
country: Brazil
facility: CLINIONCO - Clinica de Oncologia de Porto Alegre Ltda.
state: RIO Grande DO SUL
city: Porto Alegre
country: Brazil
facility: Hospital Sao Lucas da PUCRS
state: RIO Grande DO SUL
city: Rio de Janeiro
country: Brazil
facility: Instituto D'Or de Pesquisa e Ensino (IDOR)
state: RJ
city: Jau
country: Brazil
facility: Hospital Amaral Carvalho - Fundacao Dr. Amaral Carvalho
state: SAO Paulo
city: Jau
country: Brazil
facility: Fundacao Dr. Amaral Carvalho
state: SAO Paulo
city: Jau
country: Brazil
facility: Fundacao Dr.Amaral Carvalho
state: SAO Paulo
city: Sao Paulp
country: Brazil
facility: Hospital Israelita Albert Einstein
state: SAO Paulo
city: Campinas
country: Brazil
facility: Hospital das Clinicas da Faculdade de Ciencias Medicas da UNICAMP
state: SP
city: Santo Andre
country: Brazil
facility: Centro de Estudos e Pesquisas em Hematologia e Oncologia (CEPHO)
state: SP
city: Sao Paulo
country: Brazil
facility: IAMSPE-Inst. de Assist. ao Servidor Publico Estadual
state: SP
city: Rio de Janeiro
country: Brazil
facility: Hospital Universitario Pedro Ernesto - UERJ
city: Rio de Janeiro
country: Brazil
facility: Oncologia Rede D'Or
city: Calgary
country: Canada
facility: Tom Baker Cancer Centre
state: Alberta
city: Edmonton
country: Canada
facility: Cross Cancer Institute
state: Alberta
city: Vancouver
country: Canada
facility: Vancouver Prostate Centre
state: British Columbia
city: Winnipeg
country: Canada
facility: Manitoba Prostate Centre CancerCare Manitoba
state: Manitoba
city: Halifax
country: Canada
facility: NS Health Authority, Queen Elizabeth II Health Sciences Centre
state: Nova Scotia
city: Barrie
country: Canada
facility: The Male/Female Health and Research Centre
state: Ontario
city: Hamilton
country: Canada
facility: McMaster Institute of Urology @ St. Joseph's Healthcare Hamilton
state: Ontario
city: Kitchener
country: Canada
facility: Urology Associates / Urologic Medical Research
state: Ontario
city: London
country: Canada
facility: London Regional Cancer Program - Victoria Hospital, London Health Sciences Centre(LHSC)
state: Ontario
city: London
country: Canada
facility: Urology Reasearch - Victoria Hospital, London Health Sciences Centre(LHSC)
state: Ontario
city: Toronto
country: Canada
facility: SunnyBrook Health Sciences Centre
state: Ontario
city: Toronto
country: Canada
facility: University Health Network- Princess Margaret Cancer Centre
state: Ontario
city: Greenfield Park
country: Canada
facility: Urology South Shore Research
state: Quebec
city: Montreal
country: Canada
facility: Centre Hospitalier de l'Université de Montréal
state: Quebec
city: Montreal
country: Canada
facility: McGill University Health Centre
state: Quebec
city: Quebec
country: Canada
facility: CHU de Quebec
city: Santiago
country: Chile
facility: Fundacion Arturo Lopez Perez
city: Santiago
country: Chile
facility: Centro de Investigaciones Clinicas Vina del Mar
city: Temuco
country: Chile
facility: Instituto Clinico Oncologico del Sur (ICOS)
city: Vina del Mar
country: Chile
facility: Instituto Oncologico Ltda.
city: Vina del Mar
country: Chile
facility: Centro de Investigaciones Clinicas
city: Beijing
country: China
facility: Peking University First Hospital
state: Beijing
city: Beijing
country: China
facility: Beijing Cancer Hospital
state: Beijing
city: Beijing
country: China
facility: Peking University Third Hospital
state: Beijing
city: Beijing
country: China
facility: Beijing Hospital
state: Beijing
city: Beijing
country: China
facility: Peking Union Medical College Hospital
state: Beijing
city: Chongqing
country: China
facility: Chongqing Cancer Hospital
state: Chongqing
city: Guangzhou
country: China
facility: The First Affiliated Hospital of Guangzhou Medical University
state: Guangdong
city: Wuhan
country: China
facility: Zhongnan Hospital of Wuhan University
state: Hubei
city: Nanjing
country: China
facility: Office of Hongqian Guo
state: Jiangsu
city: Nanjing
country: China
facility: Jiangsu Cancer Hospital
state: Jiangsu
city: Nanjing
country: China
facility: Jiangsu Province Hospital
state: Jiangsu
city: Suzhou
country: China
facility: The Second Affiliated Hospital of Soochow University
state: Jiangsu
city: Wuxi
country: China
facility: Wuxi People's Hospital
state: Jiangsu
city: Qingdao
country: China
facility: Qingdao Municipal Hospital (East Hospital)
state: Shandong
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
city: Shanghai
country: China
facility: Huashan Hospital Fudan University
state: Shanghai
city: Shanghai
country: China
facility: Shanghai First People's Hospital
state: Shanghai
city: Shanghai
country: China
facility: Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
state: Shanghai
city: Shanghai
country: China
facility: Shanghai Changhai Hospital
state: Shanghai
city: Xi'an
country: China
facility: The First Affiliated Hospital of Xi'an Jiaotong University
state: Shanxi
city: Hangzhou
country: China
facility: The Second Affiliated Hospital of Zhejiang University School of Medicine
state: Zhejiang
city: Wenzhou
country: China
facility: The First Affiliated Hosptial of Wenzhou Medical University
state: Zhejiang
city: Hong Kong
country: China
facility: UNIMED Medical Institute Limited
city: Tianjin
country: China
facility: The Second Hospital of Tianjin Medical University
city: Copenhagen
country: Denmark
facility: Rigshospitalet 7521
state: Norrebro
city: Copenhagen
country: Denmark
facility: Copenhagen Prostate Cancer Center
state: N
city: Arhus N
country: Denmark
facility: Aarhus University Hospital
city: Copenhagen
country: Denmark
facility: Rigshospitalet
city: Frederiksberg
country: Denmark
facility: Frederiksberg Hospital
city: Herlev
country: Denmark
facility: Herlev Hospital
city: Odense C
country: Denmark
facility: Odense University Hospital
city: Vejle
country: Denmark
facility: Vejle Sygehus
city: Helsinki
country: Finland
facility: Docrates Syopasairaala
city: Helsinki
country: Finland
facility: Helsingin yliopistollinen keskussairaala, Meilahden sairaala
city: Oulu
country: Finland
facility: Oulun yliopistollinen sairaala
city: Pori
country: Finland
facility: Satakunnan keskussairaala
city: Tampere
country: Finland
facility: Tampereen yliopistollinen Sairaala
city: STRASBOURG Cedex
country: France
facility: Hopitaux Universitaires de Strasbourg - Hopital Civil
state: Alsace
city: Strasbourg
country: France
facility: Centre Paul Strauss
state: Bas-rhin
city: Strasbourg
country: France
facility: Clinique Sainte Anne
state: Bas-rhin
city: Strasbourg
country: France
facility: Societe MIM, Clinique Sainte Anne
state: Bas-rhin
city: Paris Cedex
country: France
facility: Institut Curie
state: Paris
city: Pierre Benite Cedex
country: France
facility: Centre Hospitalier Lyon Sud
state: Rhone
city: Villejuif Cedex
country: France
facility: Institut Gustave Roussy
state: VAL DE Marne
city: Angers Cedex 2
country: France
facility: Institut de Cancerologie de l'Ouest - Paul Papin
city: Avignon
country: France
facility: Institut Sainte Catherine
city: Bordeaux Cedex
country: France
facility: Institut Bergonie
city: Bordeaux Cedex
country: France
facility: Urologic Oncology Department- Institut Bergonie - Centre regional de Lutte contre le Cancer
city: Brest
country: France
facility: Cabinet de Radiologie
city: Brest
country: France
facility: CHU Brest Hopital Morvan
city: Brest
country: France
facility: Clinique pasteur Lancroze
city: Brest
country: France
facility: Clinique Pasteur-Lanroze
city: Brest
country: France
facility: CHRU de Brest
city: Colmar Cedex
country: France
facility: Hopital Pasteur
city: Colmar
country: France
facility: Hopitaux Civils de Colmar
city: Dijon
country: France
facility: Centre Regional de lutte Contre le Cancer Georges Francois Leclerc
city: Le Mans
country: France
facility: Clinique Victor Hugo
city: Lille
country: France
facility: Hopital Calude Huriez - CHU Lille
city: Lyon Cedex 03
country: France
facility: Hopital Edouard Herriot - CHU Lyon
city: Lyon Cedex
country: France
facility: Centre Leon Berard
city: Lyon
country: France
facility: Centre de Medecine Nucleaire LUMEN
city: Marseille
country: France
facility: Hopital Nord
city: Montpellier Cedex
country: France
facility: ICM Val D'Aurelle
city: Paris
country: France
facility: Hopital Europeen Georges Pompidou
city: Pierre Benite
country: France
facility: Centre Hospitalier Lyon Sud
city: Poitiers
country: France
facility: CHU Poitiers - Hopital la Miletrie
city: Saint-Herblain Cedex
country: France
facility: Institut de Cancerologie de I'Ouest - Rene Gauducheau
city: Toulouse Cedex 3
country: France
facility: Clinique Pasteur - CIMOF
city: Toulouse Cedex 3
country: France
facility: Clinique Pasteur- Service Imagerie et Radiologie
city: Toulouse Cedex 3
country: France
facility: Clinique Pasteur
city: Toulouse Cedex 9
country: France
facility: IUCT-Oncopole
city: Toulouse
country: France
facility: Institut Claudius Regaud
city: Nuertingen
country: Germany
facility: Studienpraxis Urologie
state: Baden-wuerttemberg
city: Mannheim
country: Germany
facility: Universitatsmedizin Mannheim, Medizinische Fakultat Mannheim der Universitat Heidelberg
state: Baden-wurttemberg
city: Braunschweig
country: Germany
facility: MVZ Zentrum fuer Diagnostische Radiologie und Nuklearmedizin Braunschweig GmbH
state: Niedersachsen
city: Braunschweig
country: Germany
facility: Staedtisches Klinikum Braunschweig
state: Niedersachsen
city: Hannover
country: Germany
facility: Hannover Medical School
state: Niedersachsen
city: Hannover
country: Germany
facility: Medizinische Hochschule Hannover
state: Niedersachsen
city: Aachen
country: Germany
facility: RWTH University Aachen
state: Nordrhein-westfalen
city: Aachen
country: Germany
facility: Uniklinik der RWTH Aachen
state: Nordrhein-westfalen
city: Aachen
country: Germany
facility: Clinic of Radiology
state: Nordrhein-westfalen
city: Dresden
country: Germany
facility: Universitaetsklinikum Carl Gustav Carus an der TU Dresden
state: Saxony
city: Berlin
country: Germany
facility: Charite, Campus Benjamin Franklin
city: Berlin
country: Germany
facility: Charite, Universitaetsmedizin Berlin
city: Hamburg
country: Germany
facility: Martini-Klinik am UKE GmbH
city: Kirchheim
country: Germany
facility: Diagnostikzentrum Esslingen
city: Heraklion
country: Greece
facility: University General Hospital of Heraklion, Urology Clinic
state: Crete
city: Athens
country: Greece
facility: General Hospital of Athens"Korgialeneio-Benakeio EES".Urology Clinic
city: Athens
country: Greece
facility: General Hospital of Athens "Alexandra", Therapeutic Clinic
city: Larissa
country: Greece
facility: University General Hospital of Larissa, Urology Department
city: Patra
country: Greece
facility: University General Hospital of Patras, Oncology Department, Internal Medicine Clinic
city: Thessaloniki
country: Greece
facility: General Hospital" Papageorgiou",B' Univ.Urology Clinic
city: Hong Kong
country: Hong Kong
facility: Queen Mary Hospital
city: Hong Kong
country: Hong Kong
facility: Tuen Mun Hospital
city: Shatin
country: Hong Kong
facility: Prince of Wales Hospital
city: Forli
country: Italy
facility: Laboratorio Medicina Nucleare-Ospedale G.B. Morgagni-Pierantoni
state: FC
city: Cremona
country: Italy
facility: Farmacia, Azienda Socio Sanitaria Territoriale di Cremona
city: Cremona
country: Italy
facility: Medicina Nucleare, Azienda Socio Sanitaria Territoriale di Cremona
city: Cremona
country: Italy
facility: Servizio di Radiologia, Azienda Socio Sanitaria Territoriale di Cremona
city: Cremona
country: Italy
facility: Struttura Complessa di Oncologia, Azienda Socio Sanitaria Territoriale di Cremona
city: Faenza (RA)
country: Italy
facility: U.O. di Oncologia, Ospedale Civile Degli Infermi
city: Faenza (RA)
country: Italy
facility: U.O. di Radiologia, Ospedale Civile degli Infermi
city: Lugo (RA)
country: Italy
facility: U.O. di Oncologia, Ospedale Civile Umberto I
city: Lugo (RA)
country: Italy
facility: U.O. di Radiologia, Ospedale Civile Umberto I
city: Meldola (FC)
country: Italy
facility: Laboratorio Farmaci Antiblastici
city: Meldola (FC)
country: Italy
facility: U.O. Oncologia Medica
city: Meldola (FC)
country: Italy
facility: UO Radiologia
city: Milano
country: Italy
facility: Dipartimento di Radiologia, Ospedale San Raffaele
city: Milano
country: Italy
facility: Servizio di Farmacia, Ospedale San Raffaele
city: Milano
country: Italy
facility: U.O. di Medicina Nucleare e Centro PET, Ospedale San Raffaele
city: Milano
country: Italy
facility: U.O. di Urologia, Ospedale San Raffaele
city: Milano
country: Italy
facility: Farmacia Studi Clinici e Sperimentali, Fondazione IRCCS Istituto Nazionale dei Tumori
city: Milano
country: Italy
facility: S.C. di Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori
city: Milano
country: Italy
facility: S.C. Diagnostica Radiologica 2, Fondazione IRCCS Istituto Nazionale dei Tumori
city: Milano
country: Italy
facility: Divisione di Radiologia, Istituto Europeo di Oncologia
city: Milano
country: Italy
facility: Reparto Oncologia Medica Urogenitale e Cervico Facciale, Istituto Europeo di Oncologia
city: Milano
country: Italy
facility: Servizio Farmacia, Istituto Europeo di Oncologia
city: Modena
country: Italy
facility: Farmacia Interna, Azienda Ospedaliero-Universitaria Policlinico di Modena
city: Modena
country: Italy
facility: Medicina Nucleare, Azienda Ospedaliero-Universitaria Policlinico di Modena
city: Modena
country: Italy
facility: Radiologia I, Azienda Ospedaliero-Universitaria Policlinico di Modena
city: Napoli
country: Italy
facility: U.O.S.C. di Oncologia Medica, A.O.R.N. "A. Cardarelli"
city: Orbassano (TO)
country: Italy
facility: Farmacia Ospedaliera, AOU San Luigi Gonzaga
city: Orbassano (TO)
country: Italy
facility: SCDU Oncologia Medica II Pad, AOU San Luigi Gonzaga
city: Orbassano (TO)
country: Italy
facility: SCDU Radiodiagnostica, AOU San Luigi Gonzaga
city: Orbassano (TO)
country: Italy
facility: SS Medicina Nucleare, AOU San Luigi Gonzaga
city: Padova
country: Italy
facility: Farmacia, Istituto Oncologico Veneto (IOV)
city: Padova
country: Italy
facility: IRCCS - Istituto Oncologico Veneto (IOV), UOC Oncologia Medica 1
city: Padova
country: Italy
facility: Medicina Nucleare, Istituto Oncologico Veneto (IOV)
city: Padova
country: Italy
facility: UOC Radiodiagnostica Oncologica, Istituto Oncologico Veneto (IOV)
city: Ravenna
country: Italy
facility: Dipartimento di Onco-Ematologia Ospedale Santa Maria delle Croci
city: Ravenna
country: Italy
facility: Servizio di Farmacia, AUSL di Ravenna
city: Ravenna
country: Italy
facility: Servizio di Radiologia, AUSL di Ravenna
city: Roma
country: Italy
facility: Azienda Ospedaliera S. Camillo Forlanini, UOC per il governo clinico in Oncologia Medica
city: Trento
country: Italy
facility: U.O. di Oncologia Medica, Ospedale Santa Chiara
city: Trento
country: Italy
facility: U.O. Farmacia, Ospedale Santa Chiara
city: Trento
country: Italy
facility: U.O. Radiologia, Ospedale Santa Chiara
city: Goyang-si
country: Korea, Republic of
facility: National Cancer Center
state: Gyeonggi-do
city: Hwasun-gun
country: Korea, Republic of
facility: Chonnam National University Hwasun Hospital
state: Jeonnam
city: Incheon
country: Korea, Republic of
facility: Gachon University Gil Medical Center
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University Health System
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Seoul
country: Korea, Republic of
facility: Gangnam Severance Hospital, Yonsei University Health System
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Cheras
country: Malaysia
facility: Universiti Kebangsaan Malaysia Medical Centre
state: Kuala Lumpur
city: Kuching
country: Malaysia
facility: Sarawak General Hospital
state: Sarawak
city: Subang Jaya
country: Malaysia
facility: Subang Jaya Medical Centre Sdn. Bhd.
state: Selangor Darul Ehsan
city: Kuala Lumpur
country: Malaysia
facility: Hospital Kuala Lumpur
city: Kuala Lumpur
country: Malaysia
facility: University Malaya Medical Centre
city: Maastricht
country: Netherlands
facility: Maastricht University Medical Centre
state: AZ
city: Eindhoven
country: Netherlands
facility: Catharina Ziekenhuis
state: Noord-brabant
city: Amsterdam
country: Netherlands
facility: Netherlands Cancer Institute
city: Dordrecht
country: Netherlands
facility: Albert Schweitzer Ziekenhuis
city: Groningen
country: Netherlands
facility: University Medical Center Groningen
city: Nijmegen
country: Netherlands
facility: Radboud University Nijmegen Medical Centre
city: Christchurch
country: New Zealand
facility: Canterbury District Health Board
state: Canterbury
city: Palmerston North
country: New Zealand
facility: Palmerston North Hospital
state: Manawatu
city: Auckland
country: New Zealand
facility: Cancer and Blood Research
city: Hamilton
country: New Zealand
facility: Waikato Urology Research LTD
city: Gdansk
country: Poland
facility: Uniwersyteckie Centrum Kliniczne
city: Kielce
country: Poland
facility: UROMEDYK, Poradnia Urologiczna
city: Krakow
country: Poland
facility: Malopolskie Centrum Medyczne s.c.
city: Lublin
country: Poland
facility: Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego SPZOZ
city: Slupsk
country: Poland
facility: Wojewodzki Szpital Specjalistyczny im. Janusza. Korczaka
city: Wroclaw
country: Poland
facility: Profesorskie Centrum Medyczne Optimum
city: Wroclaw
country: Poland
facility: Centrum Medyczne Melita Medical
city: Wroclaw
country: Poland
facility: Wro Medica
city: Wroclaw
country: Poland
facility: Lexmedica
city: Moscow
country: Russian Federation
facility: Federal State Budgetary Institution "N.N. Blokhin Russian Cancer Research Center"
city: Moscow
country: Russian Federation
facility: P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research
city: Saint-Petersburg
country: Russian Federation
facility: State Budgetary Healthcare Institution City Multifield Hospital No.2
city: Saint-Petersburg
country: Russian Federation
facility: SBEI HPE "First Pavlov State Medical University of St. Petersburg" of
city: Saint-Petersburg
country: Russian Federation
facility: SBEI HPE "First Pavlov State Medical University of St. Petersburg" of
city: Saint-Petersburg
country: Russian Federation
facility: Saint-Petersburg State Budgetary Healthcare Institution "Hospital for Veterans of War"
city: Saint-Petersburg
country: Russian Federation
facility: SBHI "Saint-Petersburg clinical scientific
city: Ufa
country: Russian Federation
facility: SBEI of HPE "Bashkir State Medical University" of MoH of the RF
city: Belgrade
country: Serbia
facility: Clinical Center Of Serbia, Clinic of Urology
city: Belgrade
country: Serbia
facility: Clinical Center "Dr Dragisa Misovic -Dedinje", Clinic of Urology
city: Belgrade
country: Serbia
facility: Clinical Center "Bezanijska Kosa", Department of Urology
city: Belgrade
country: Serbia
facility: Clinical Center Zemun
city: Singapore
country: Singapore
facility: National University Hospital
city: Singapore
country: Singapore
facility: National Cancer Centre Singapore
city: Banska Bystrica
country: Slovakia
facility: Fakultna nemocnica s poliklinikou F.D. Roosevelta
city: Banska Bystrica
country: Slovakia
facility: Institut nuklearnej a molekularnej mediciny
city: Bratislava
country: Slovakia
facility: Bratislavske radiodiagnosticke centrum, a.s.
city: Bratislava
country: Slovakia
facility: CUIMED, s.r.o., Urologicka ambulancia
city: Kosice
country: Slovakia
facility: Vychodoslovensky onkologicky ustav, a.s.
city: Kosice
country: Slovakia
facility: Vychodoslovensky onkologicky ustav, a.s.
city: Kosice
country: Slovakia
facility: Institut nuklearnej a molekularnej mediciny
city: Martin
country: Slovakia
facility: Univerzitna nemocnica Martin
city: Nitra
country: Slovakia
facility: IZOTOPCENTRUM, s.r.o.
city: Nitra
country: Slovakia
facility: Jessenius-diagnosticke centrum, a.s.
city: Nitra
country: Slovakia
facility: UROEXAM spol. s r.o. urologicka ambulancia
city: Presov
country: Slovakia
facility: Alfamedis, s.r.o.
city: Presov
country: Slovakia
facility: MILAB s.r.o., UROCENTRUM
city: Presov
country: Slovakia
facility: Vivamed, s.r.o
city: Ruzomberok
country: Slovakia
facility: UVN SNP - FN Ruzomberok, Pracovisko Nuklearnej mediciny CCSR
city: Skalica
country: Slovakia
facility: Fakultna nemocnica s Poliklinikou Skalica a.s
city: Trnava
country: Slovakia
facility: GAMMALAB, spol. s.r.o., Oddelenie nuklearnej mediciny
city: Trnava
country: Slovakia
facility: GAMMALAB, spol.s.r.o., Oddelenie nuklearnej mediciny
city: Zilina
country: Slovakia
facility: KK MED s.r.o.
city: Zilina
country: Slovakia
facility: Fakultna nemocnica s poliklinikou Zilina, Urologicke oddelenie
city: Santiago de Compostela
country: Spain
facility: Hospital Clinico Universitario de Santiago de Compostela
state: A Coruna
city: Palma de Mallorca
country: Spain
facility: Hospital Universitari Son Espases,
state: Baleares
city: Badalona
country: Spain
facility: Hospital Germans Trias i Pujol
state: Barcelona
city: Manresa
country: Spain
facility: ALTAHIA. Xarxa Assistencial Universitaria de Manresa
state: Barcelona
city: Sabadell
country: Spain
facility: Hospital Universitario Parc Tauli
state: Barcelona
city: Gerona
country: Spain
facility: ICO Girona-Hospital Universitari de Girona Dr. Josep Trueta
state: Cataluna
city: Pamplona
country: Spain
facility: Hospital de Navarra
state: Navarra
city: A Coruna
country: Spain
facility: Complejo Hospitalario Universitario A Coruna
city: Barcelona
country: Spain
facility: Hospital Del Mar
city: Barcelona
country: Spain
facility: Cetir Centre Medic, S.L.
city: Barcelona
country: Spain
facility: Hospital Clinic de Barcelona
city: Madrid
country: Spain
facility: Hospital Universitario de la Princesa
city: Madrid
country: Spain
facility: MD Anderson Cancer Center
city: Madrid
country: Spain
facility: Hospital Universitario 12 de octubre
city: Goteborg
country: Sweden
facility: Urologmottagningen
city: Malmo
country: Sweden
facility: Diagnostiskt centrum for bild- och funktionsmedicin
city: Malmo
country: Sweden
facility: Urologiska Kliniken
city: Molnlycke
country: Sweden
facility: Apoteket AB Kliniska Provningar Molnlycke
city: Solna
country: Sweden
facility: Karolinska Universitetssjukhuset
city: Stockholm
country: Sweden
facility: Urologmottagningen
city: Umea
country: Sweden
facility: Urologkliniken
city: Örebro
country: Sweden
facility: Urologiska Kliniken
city: Chiayi County
country: Taiwan
facility: Chang Gung Medical Fundation, Chiayi Branch(Chiayi Chang Gung Memorial Hospital)
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Chung-Ho Memorial Hospital
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Veterans General Hospital
city: Kaohsiung
country: Taiwan
facility: Chang Gung Medical Fundation,Kaohsiung (Kaohsiung Chang Gung Memorial Hospital)
city: Keelung City
country: Taiwan
facility: Chang Gung Memorial Hospital, Keelung Branch (Keelung Chang Gung Memorial Hospital)
city: Taichung
country: Taiwan
facility: China Medical University Hospital
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital
city: Tainan City
country: Taiwan
facility: Chi Mei Medical Centre
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
city: Taoyuan County
country: Taiwan
facility: Chang-Gung Memorial Hospital at Linkuo
city: Muang
country: Thailand
facility: Maharaj Nakorn Chiang Mai Hospital
state: Chiang MAI
city: Hat Yai
country: Thailand
facility: Songklanagarind hospital
state: Songkla
city: Bangkok
country: Thailand
facility: King Chulalongkorn Memorial Hospital, Chulalongkorn University
city: Bangkok
country: Thailand
facility: Rajavithi Hospital
city: Adana
country: Turkey
facility: Cukurova Universitesi Tip Fakultesi
city: Ankara
country: Turkey
facility: Hacettepe Universitesi Tip Fakultesi
city: Istanbul
country: Turkey
facility: Istanbul Universitesi Cerrahpasa Tip Fakultesi
city: Izmir
country: Turkey
facility: Izmir Bozyaka Egitim Arastirma Hastanesi
city: Manisa
country: Turkey
facility: Celal Bayar Universitesi Tip Fakultesi
city: Chernivtsi
country: Ukraine
facility: RCI Chernivtsi Regional Clinical Hospital
city: Dnipropetrovsk
country: Ukraine
facility: CI Dnipropetrovsk I.I. Mechnykov RCH, Department of Urology #2
city: Kharkiv
country: Ukraine
facility: CHI V.I.Shapoval RCC of Urology and Nephrology, Dep. Of Urology#4
city: Kyiv
country: Ukraine
facility: Kyiv City Clinical Hospital #3, Department of Urology
city: Uzhgorod
country: Ukraine
facility: Central City Clinical Hospital, City Oncological Center
city: Zaporizhzhia
country: Ukraine
facility: CI Zaporizhzhia Regional Clinical Hospital, Dep. Of Urology,
city: Northwood
country: United Kingdom
facility: East and North Hertfordshire NHS Trust
state: Middlesex
city: Belfast
country: United Kingdom
facility: Belfast Health and Social Care Trust
state: Northern Ireland
city: Sutton
country: United Kingdom
facility: Royal Marsden NHS Foundation Trust
state: Surrey
city: Newcastle upon Tyne
country: United Kingdom
facility: The Newcastle upon Tyne Hospitals NHS Foundation Trust
state: Tyne and Wear
city: Birmingham
country: United Kingdom
facility: University Hospitals Birmingham NHS Foundation Trust
city: Birmingham
country: United Kingdom
facility: University Hospitals Birmingham NHS Foundation Trust
city: Bristol
country: United Kingdom
facility: University Hospitals Bristol NHS Foundation Trust
city: Bristol
country: United Kingdom
facility: University Hospitals Bristol NHS Foundation Trust
city: Cambridge
country: United Kingdom
facility: Cambridge University Hospitals NHS Foundation Trust
city: London
country: United Kingdom
facility: University College Hospitals NHS Trust
city: London
country: United Kingdom
facility: Imperial College Healthcare NHS Trust
city: London
country: United Kingdom
facility: University College London Hospitals NHS Foundation Trust
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust
city: Oxford
country: United Kingdom
facility: Oxford University Hospitals NHS Trust
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
citation: De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J, Sugg J, Lin X, Shen Q, Sternberg CN. Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? Future Oncol. 2022 Nov;18(35):3867-3874. doi: 10.2217/fon-2022-0661. Epub 2022 Oct 13.
citation: Cella D, Ganguli A, Turnbull J, Rohay J, Morlock R. US Population Reference Values for Health-Related Quality of Life Questionnaires Based on Demographics of Patients with Prostate Cancer. Adv Ther. 2022 Aug;39(8):3696-3710. doi: 10.1007/s12325-022-02204-3. Epub 2022 Jun 22.
citation: Joshua AM, Armstrong A, Crumbaker M, Scher HI, de Bono J, Tombal B, Hussain M, Sternberg CN, Gillessen S, Carles J, Fizazi K, Lin P, Duggan W, Sugg J, Russell D, Beer TM. Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. Eur J Cancer. 2022 Jul;170:285-295. doi: 10.1016/j.ejca.2022.04.005. Epub 2022 May 26.
citation: De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J, Sugg J, Lin X, Shen Q, Sternberg CN. Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. Eur J Cancer. 2021 Dec;159:237-246. doi: 10.1016/j.ejca.2021.10.015. Epub 2021 Nov 14.
citation: Saad F, Sternberg CN, Efstathiou E, Fizazi K, Modelska K, Lin X, Sugg J, Steinberg J, Noerby B, Shore ND, Hussain M. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. Eur Urol. 2020 Dec;78(6):847-853. doi: 10.1016/j.eururo.2020.08.025. Epub 2020 Oct 1.
citation: Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M; PROSPER Investigators. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Jun 4;382(23):2197-2206. doi: 10.1056/NEJMoa2003892. Epub 2020 May 29.
citation: Tombal B, Saad F, Penson D, Hussain M, Sternberg CN, Morlock R, Ramaswamy K, Ivanescu C, Attard G. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2019 Apr;20(4):556-569. doi: 10.1016/S1470-2045(18)30898-2. Epub 2019 Feb 12.
citation: Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung D, Krivoshik A, Sternberg CN. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.